ALLMedicine™ Folliculitis Center

Jan 31st, 2023 - New treatments for psoriasis constitute an embarrassment of riches compared to any other area of dermatology. Despite the many advances over the last 25 years, additional topical and systemic treatments have recently become available.

Jan 31st, 2023 - Folliculitis decalvans (FD) is a rare primary neutrophilic scarring alopecia whose etiology has not been completely elucidated yet. To determine if the follicular microbiota residing in FD-affected hair follicles had a distinct microbiological sig...

Jan 29th, 2023 - Epidermal growth factor receptor (EGFR) is one of therapeutic targets in oncology for solid tumors originating from epithelial tissue, such as non-small-cell lung carcinoma (NSCLC) and breast cancer. EGFR inhibitors used in cancer treatment may ca...

Jan 21st, 2023 - Comment on 'Eosinophilic pustular folliculitis developing at the site of COVID-19 vaccination'.|2023|Martora F,Battista T,Fabbrocini G,Potestio L,|prevention & control,adverse effects,etiology,

Dec 28th, 2022 - Acne fulminans (AF) is an uncommon variant of inflammatory acne with abrupt eruption of painful nodules, pustules, and hemorrhagic ulcerations, often associated with systemic symptoms. Paradoxical adverse reactions to tumor necrosis (TNF)-alpha in...

Nov 8th, 2022 - Acne keloidalis nuchae (AKN) is one of the chronic forms of scarring folliculitis, affecting predominantly the occipital scalp, seen mostly in men of African descent. Duobrii has the advantage of being the only high potency topical steroid-retinoi...

Sep 22nd, 2022 - Malassezia folliculitis is a common disease of young and middle-aged people. It is an inflammatory disease caused by Malassezia infection. Generally, Topical or systemic use of antifungal drugs are the first choice for treatment but sometimes are ...

May 2nd, 2022 - Ialuxid® Gel is a non-antibiotic treatment in gel indicated for use in a variety of skin conditions, and also in case of infection. Its principal ingredient is Ialuvance™ Complex, a proprietary association of hydrogen peroxide, hyaluronic acid, an...

Apr 6th, 2022 - Eye infection is a prevalent problem in primary care and remains a crucial healthcare concern. According to the American Academy of Ophthalmology (AAO), herpes simplex virus (HSV) keratitis (HSK) is the leading cause of infectious blindness worldw...

Dec 14th, 2021 - The first-line drug treatment for mild-moderate AD are currently topical corticosteroids (TCS) with recognized efficacy. However, their prolonged or inappropriate use, can lead to local adverse effects. Side-effects of topical corticosteroids comp...

Jan 31st, 2023 - New treatments for psoriasis constitute an embarrassment of riches compared to any other area of dermatology. Despite the many advances over the last 25 years, additional topical and systemic treatments have recently become available.

Dec 1st, 2022 - Many patients with hidradenitis suppurativa (HS) return to emergency departments – not to dermatology clinics – for their ongoing care, according to a study of a large national administrative data set. “Patients with HS presenting to the ED for th.

Dec 1st, 2022 - Many patients with hidradenitis suppurativa (HS) return to emergency departments – not to dermatology clinics – for their ongoing care, according to a study of a large national administrative data set. “Patients with HS presenting to the ED for th...

Sep 11th, 2022 - The FDA approved the first-in-class oral tyrosine kinase 2 (TYK2) inhibitor deucravacitinib (Sotyktu) for moderate-to-severe plaque psoriasis, Bristol Myers Squibb announced. The indication limits use to adults who are candidates for systemic ther...

Jun 13th, 2022 - The FDA approved the Janus kinase (JAK) inhibitor baricitinib (Olumiant) as the first systemic treatment for alopecia areata. The approval pertains to adults with severe alopecia areata, which affects more than 300,000 people in the U.S. each year...